Hokkaido University · Faculty of Medicine / Graduate School of Medicine / Medical Research Institute

Research keywordscirrhosis cachexia・hepatocellular carcinoma・hepatitis C eradication・direct-acting antivirals・liver fibrosis biomarkers・sarcopenia biomarkers・hepatic encephalopathy・atezolizumab bevacizumab

This is a public-data preview. Personalized fit, contact angles, and saved workflows require sign-in.

• Soluble Cluster of Differentiation 14 as a Prognostic Marker in Decompensated Cirrhosis With Water Retention2026 · Hepatology Research, 2026年04月
• Continuity of long-term follow-up in patients with chronic hepatitis C after sustained virologic response following direct-acting antiviral therapy: a nationwide real-world multicenter cohort study in Japan.2026 · Journal of gastroenterology, 2026年01月27日,
• Serum fibroblast growth factor 21 is a novel biomarker of cachexia in chronic liver disease.2026 · Frontiers in nutrition, 13, 1730695, 1730695, 2026年,
• Tenofovir alafenamide prevents HBV reactivation in anticancer/immunosuppression: 24-month multicentre prospective study2026 · Journal of Infection, 92, 4, 106715, 106715, 2026年04月,

• Official profile